ArticleActa Cardiologica Sinica2026
Exosomal MicroRNA-1 Regulate Cx43 Expression via Tbx18 in Culture Atrial Fibroblasts under Rapid Electrical Stimulation.
Article in Acta Cardiologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: MicroRNAs (miRs) are involved in cardiac remodeling, and tachyarrhythmia can regulate miR expression. While microRNA-1 (miR-1) is essential for genes involved in atrial tachyarrhythmia, the effect of rapid electrical stimulation (RES) on fibroblast-derived exosomal miR-1 is unknown. This study investigated the molecular regulation of exosomal miR-1 and its therapeutic potential in human atrial fibroblasts (HCF-aa) using RES. Methods: HCF-aa were cultured in a pacer dish and exposed to RES (0.5 V/cm and 10 Hz). We then investigated whether miR-1 expression could be regulated in HCF-aa under RES, and examined the effects on T-box transcription factor 18 (Tbx18) and connexin 43 (Cx43) protein levels. Results: RES initially upregulated and subsequently downregulated exosomal miR-1 expression. Overexpression of miR-1 reduced Tbx18 levels but increased Cx43 expression in HCF-aa after 64 hours of RES. Conversely, mutant miR-1 and miR-1 antagomir significantly reduced Cx43 expression. Luciferase reporter assays indicated that miR-1 antagomir pretreatment suppressed the transcriptional activity of Tbx18 on the Cx43 promoter, an effect reversed by mutating the Tbx18 binding site. RES for 24 hours increased exosomal miR-1 and led to a reduction in Tbx18 3'-UTR luciferase activity; this effect was mitigated by mutating the hsa-miR-1-3p binding site. Immunohistochemical staining confirmed that miR-1 antagomir downregulated Cx43, while Tbx18 siRNA upregulated Cx43 in RES-exposed HCF-aa. Conclusions: In HCF-aa under RES, miR-1 and Tbx18 regulated Cx43 expression, with miR-1 modulating Cx43 through Tbx18. These findings provide insights into the molecular mechanisms of cardiac remodeling and offer potential therapeutic targets for treating tachyarrhythmia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.